- Clinical trial conducted in 3,219 African participants... WHO PQ review approaching completion
- UNICEF supply expected in H2 2026, backed by cost-competitive production using proprietary CRM197
[by Ji, Yong Jun] EuBiologics, a Korean 에볼루션 바카라 사이트 manufacturer, announced on November 13 that the results of its multinational Phase 3 clinical trial for the typhoid conjugate 에볼루션 바카라 사이트, EuTYPH-C injection, were published in the December issue of the international academic journal Lancet Global Health.
The study, conducted in Senegal and Kenya with a total of 3,219 participants aged 6 months to 45 years, demonstrated clear immunological non-inferiority to the Typbar-TCV, the typhoid conjugate 에볼루션 바카라 사이트 prequalified by the WHO.
The study was carried out in collaboration with the international health organization PATH and funded by the RIGHT Foundation. Its direct implementation in African countries where the 에볼루션 바카라 사이트 is intended for use further enhances its global credibility. According to the publication, EuTYPH-C injection achieved a seroconversion rate of 99.6-100% (a fourfold increase in anti-Vi antibodies) at 28 days in infants aged 9-12 months, demonstrating an immune response comparable to or exceeding that of the WHO prequalified 에볼루션 바카라 사이트. No serious adverse events (SAEs) were reported in either 에볼루션 바카라 사이트 group.
에볼루션 바카라 사이트 received export approval for EuTYPH-C injection from the Ministry of Food and Drug Safety (MFDS) earlier this year and formally applied for WHO Prequalification (PQ) in May, which is currently under review. PQ approval would allow the company to enter the Gavi and UNICEF procurement markets, with large-scale supply anticipated to begin in H2 2026. 에볼루션 바카라 사이트 also participated in the UNICEF Award and Tender process in August.
Typhoid fever is a widespread infectious disease in developing regions, with more than seven million cases reported annually. In recent years, global demand for typhoid vaccines has risen sharply, especially across Africa and South Asia. EuTYPH-C injection, which uses EuBiologics' proprietary carrier protein (CRM197), is considered to have a production-cost advantage over competing products thanks to the company’s high-efficiency conjugation technology and consistent manufacturing quality.
EuBiologics has already supplied more than 200 million doses to the global procurement market through its oral cholera vaccine (the Euvichol series), currently distributed to UNICEF. EuTYPH-C injection is expected to become the company’s ‘second Euvichol’ once WHO prequalification is obtained. To support expansion of its core pipeline, including typhoid and future meningococcal vaccines, the company is also considering the construction of a new manufacturing facility, including a dedicated finished-product plant.
"The publication of clinical results for EuTYPH-C injection, developed using our proprietary carrier protein (CRM197), in a world-renowned academic journal marks a significant milestone for Korean vaccine technology. Through WHO prequalification and participation in UNICEF procurement programs, we aim to contribute new supply stability to the global typhoid vaccine market," an EuBiologics official said.